You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSparfloxacin
Accession NumberDB01208  (APRD01231)
TypeSmall Molecule
GroupsApproved
DescriptionSparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Structure
Thumb
Synonyms
cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Sparfloxacin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ZagamNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ90AGA787L
CAS number110871-86-8
WeightAverage: 392.3998
Monoisotopic: 392.165997
Chemical FormulaC19H22F2N4O3
InChI KeyDZZWHBIBMUVIIW-DTORHVGOSA-N
InChI
InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
IUPAC Name
5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
C[[email protected]]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O
Pharmacology
IndicationFor the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae).
Structured Indications Not Available
PharmacodynamicsSparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent in the same class as ofloxacin and norfloxacin. Sparfloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. Quinolones differ in chemical structure and mode of action from (beta)-lactam antibiotics. Quinolones may, therefore, be active against bacteria resistant to (beta)-lactam antibiotics. Although cross-resistance has been observed between sparfloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to sparfloxacin. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus.
Mechanism of actionThe bactericidal action of sparfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
DNA topoisomerase 2-alphaProteinyes
inhibitor
HumanP11388 details
Related Articles
AbsorptionWell absorbed following oral administration with an absolute oral bioavailability of 92%. Unaffected by administration with milk or food, however concurrent administration of antacids containing magnesium hydroxide and aluminum hydroxide reduces the oral bioavailability of sparfloxacin by as much as 50%.
Volume of distributionNot Available
Protein bindingLow plasma protein binding in serum at about 45%.
Metabolism

Hepatic. Metabolized primarily by phase II glucuronidation to form a glucuronide conjugate. Metabolism does not utilize or interfere with the cytochrome P450 enzyme system.

Route of eliminationNot Available
Half lifeMean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance <50 mL/min).
ClearanceNot Available
ToxicitySingle doses of sparfloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post-treatment observation period at the highest oral doses tested, up to 5000 mg/kg in either rodent species, or up to 600 mg/kg in the dog. Clinical signs observed included inactivity in mice and dogs, diarrhea in both rodent species, and vomiting, salivation, and tremors in dogs.
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Sparfloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Sparfloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Sparfloxacin.Experimental, Illicit
AcarboseSparfloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved
AcenocoumarolSparfloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Sparfloxacin can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Sparfloxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Sparfloxacin.Approved
AfatinibThe serum concentration of Sparfloxacin can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideSparfloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Sparfloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Sparfloxacin.Experimental
AlectinibThe serum concentration of Sparfloxacin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Sparfloxacin can be increased when it is combined with Alfentanil.Approved, Illicit
AlogliptinSparfloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe serum concentration of Sparfloxacin can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Sparfloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Sparfloxacin.Approved
Aminohippuric acidThe serum concentration of Sparfloxacin can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Sparfloxacin.Approved
AmiodaroneThe serum concentration of Sparfloxacin can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Sparfloxacin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Sparfloxacin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Sparfloxacin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Sparfloxacin can be increased when it is combined with Amsacrine.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Sparfloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Sparfloxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Sparfloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
AstemizoleThe serum concentration of Sparfloxacin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Sparfloxacin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Sparfloxacin can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Sparfloxacin can be increased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Sparfloxacin.Approved
AzithromycinThe serum concentration of Sparfloxacin can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Sparfloxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Sparfloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Sparfloxacin.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
BenzocaineThe serum concentration of Sparfloxacin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Sparfloxacin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sparfloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Sparfloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Sparfloxacin.Approved, Investigational
BiperidenThe serum concentration of Sparfloxacin can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BosutinibThe serum concentration of Sparfloxacin can be increased when it is combined with Bosutinib.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Sparfloxacin.Approved
BromocriptineThe serum concentration of Sparfloxacin can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Sparfloxacin.Approved
BuprenorphineThe serum concentration of Sparfloxacin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Sparfloxacin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfloxacin.Approved
CaffeineThe serum concentration of Sparfloxacin can be increased when it is combined with Caffeine.Approved
CalciumCalcium can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinThe serum concentration of Sparfloxacin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Sparfloxacin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Sparfloxacin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Sparfloxacin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Sparfloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Sparfloxacin can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Sparfloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
ChlorpromazineThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Sparfloxacin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Sparfloxacin can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Sparfloxacin.Approved, Investigational
CilazaprilThe serum concentration of Sparfloxacin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Sparfloxacin can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Sparfloxacin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Sparfloxacin can be increased when it is combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Sparfloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Sparfloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Sparfloxacin.Approved
ClofazimineThe serum concentration of Sparfloxacin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Sparfloxacin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinClonixin may increase the neuroexcitatory activities of Sparfloxacin.Approved
ClotrimazoleThe serum concentration of Sparfloxacin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Sparfloxacin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Sparfloxacin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Sparfloxacin can be increased when it is combined with Colforsin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Sparfloxacin.Approved
CrizotinibThe serum concentration of Sparfloxacin can be increased when it is combined with Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Sparfloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sparfloxacin.Approved, Investigational
CyclosporineThe serum concentration of Sparfloxacin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Sparfloxacin.Investigational
DaclatasvirThe serum concentration of Sparfloxacin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Sparfloxacin can be increased when it is combined with Dactinomycin.Approved
DapagliflozinSparfloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DasatinibThe serum concentration of Sparfloxacin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Sparfloxacin can be decreased when it is combined with Daunorubicin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Sparfloxacin.Investigational
DesipramineThe serum concentration of Sparfloxacin can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sparfloxacin.Approved
DesloratadineThe serum concentration of Sparfloxacin can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Sparfloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Sparfloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Sparfloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Sparfloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Sparfloxacin.Vet Approved
DextromethorphanThe serum concentration of Sparfloxacin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
DicoumarolSparfloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Sparfloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Sparfloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Sparfloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Sparfloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Sparfloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
DihydroergotamineThe serum concentration of Sparfloxacin can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Sparfloxacin can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Sparfloxacin can be increased when it is combined with Dipyridamole.Approved
DisopyramideSparfloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfloxacin.Approved, Investigational
DoxazosinThe serum concentration of Sparfloxacin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Sparfloxacin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Sparfloxacin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Sparfloxacin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Sparfloxacin can be increased when it is combined with Dronedarone.Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
DulaglutideSparfloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Sparfloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Sparfloxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Sparfloxacin.Investigational
ElbasvirThe serum concentration of Sparfloxacin can be increased when it is combined with Elbasvir.Approved
EmpagliflozinSparfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe serum concentration of Sparfloxacin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Sparfloxacin can be increased when it is combined with Enzalutamide.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Sparfloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Sparfloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Sparfloxacin.Approved
ErgonovineThe serum concentration of Sparfloxacin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Sparfloxacin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Sparfloxacin can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstramustineThe serum concentration of Sparfloxacin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Sparfloxacin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Sparfloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Sparfloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
Ethyl biscoumacetateSparfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Sparfloxacin.Approved
EtoposideThe serum concentration of Sparfloxacin can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
EtravirineThe serum concentration of Sparfloxacin can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Sparfloxacin.Approved
ExenatideSparfloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Sparfloxacin.Investigational
FelodipineThe serum concentration of Sparfloxacin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Sparfloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
FentanylThe serum concentration of Sparfloxacin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FexofenadineThe serum concentration of Sparfloxacin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Sparfloxacin can be increased when it is combined with Fidaxomicin.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Sparfloxacin.Investigational
FluconazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sparfloxacin.Approved
FluindioneSparfloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Sparfloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Sparfloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Sparfloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Sparfloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Sparfloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Sparfloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Sparfloxacin.Approved
FluoxetineThe serum concentration of Sparfloxacin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Sparfloxacin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Sparfloxacin can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Sparfloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Sparfloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Sparfloxacin.Approved
FlurazepamThe serum concentration of Sparfloxacin can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Sparfloxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Sparfloxacin.Approved
FluvoxamineThe serum concentration of Sparfloxacin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Sparfloxacin.Approved, Investigational, Withdrawn
GefitinibThe serum concentration of Sparfloxacin can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Sparfloxacin can be increased when it is combined with Genistein.Investigational
GliclazideSparfloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSparfloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSparfloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideThe serum concentration of Sparfloxacin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Sparfloxacin can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Sparfloxacin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Sparfloxacin can be increased when it is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Sparfloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sparfloxacin.Approved, Vet Approved
IbuprofenIbuprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Sparfloxacin.Approved
IdelalisibThe serum concentration of Sparfloxacin can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Sparfloxacin can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Sparfloxacin can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Sparfloxacin can be decreased when it is combined with Indinavir.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
Insulin AspartSparfloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSparfloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSparfloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSparfloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSparfloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSparfloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron saccharate.Approved
IsavuconazoniumThe serum concentration of Sparfloxacin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Sparfloxacin.Investigational
ItraconazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sparfloxacin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Sparfloxacin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
KetamineThe serum concentration of Sparfloxacin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Sparfloxacin.Approved
LanreotideSparfloxacin may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Sparfloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe serum concentration of Sparfloxacin can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
LevofloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Sparfloxacin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Sparfloxacin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Sparfloxacin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Sparfloxacin can be decreased when it is combined with Liotrix.Approved
LiraglutideSparfloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe serum concentration of Sparfloxacin can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the neuroexcitatory activities of Sparfloxacin.Investigational
LomitapideThe serum concentration of Sparfloxacin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Sparfloxacin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Sparfloxacin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Sparfloxacin can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
LosartanThe serum concentration of Sparfloxacin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Sparfloxacin can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
LumacaftorThe serum concentration of Sparfloxacin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe serum concentration of Sparfloxacin can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Sparfloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Sparfloxacin.Investigational
MebendazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecaserminSparfloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Sparfloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
MefloquineThe serum concentration of Sparfloxacin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Sparfloxacin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Sparfloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
MeprobamateThe serum concentration of Sparfloxacin can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
MetforminSparfloxacin may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe serum concentration of Sparfloxacin can be increased when it is combined with Methadone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sparfloxacin.Approved, Vet Approved
MetoprololThe serum concentration of Sparfloxacin can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Sparfloxacin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Sparfloxacin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Sparfloxacin can be decreased when it is combined with Mifepristone.Approved, Investigational
MiglitolSparfloxacin may increase the hypoglycemic activities of Miglitol.Approved
MitomycinThe serum concentration of Sparfloxacin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Sparfloxacin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Sparfloxacin.Approved, Vet Approved
MorphineThe serum concentration of Sparfloxacin can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sparfloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Sparfloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Sparfloxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Sparfloxacin.Approved
NaltrexoneThe serum concentration of Sparfloxacin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
NaringeninThe serum concentration of Sparfloxacin can be increased when it is combined with Naringenin.Experimental
NateglinideSparfloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Sparfloxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
NefazodoneThe serum concentration of Sparfloxacin can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Sparfloxacin can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Sparfloxacin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Sparfloxacin.Approved
NicardipineThe serum concentration of Sparfloxacin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Sparfloxacin can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
NilotinibThe serum concentration of Sparfloxacin can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Withdrawn
NisoldipineThe serum concentration of Sparfloxacin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Sparfloxacin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine.Approved
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Sparfloxacin.Investigational
NorethisteroneThe serum concentration of Sparfloxacin can be decreased when it is combined with Norethisterone.Approved
OctreotideSparfloxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Sparfloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Sparfloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
OmeprazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Sparfloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Sparfloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Sparfloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
P-NitrophenolThe serum concentration of Sparfloxacin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfloxacin.Approved, Vet Approved
Palmitic AcidThe serum concentration of Sparfloxacin can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Sparfloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved
ParoxetineThe serum concentration of Sparfloxacin can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideSparfloxacin may increase the hypoglycemic activities of Pasireotide.Approved
PentamidineSparfloxacin may increase the hypoglycemic activities of Pentamidine.Approved
PerindoprilThe serum concentration of Sparfloxacin can be increased when it is combined with Perindopril.Approved
PhenindioneSparfloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Sparfloxacin can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonSparfloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sparfloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
PimozideThe serum concentration of Sparfloxacin can be increased when it is combined with Pimozide.Approved
PioglitazoneSparfloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Sparfloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
Platelet Activating FactorThe serum concentration of Sparfloxacin can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Sparfloxacin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideSparfloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Sparfloxacin.Approved, Nutraceutical
PravastatinThe serum concentration of Sparfloxacin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Sparfloxacin can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Sparfloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sparfloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Sparfloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Sparfloxacin.Experimental
ProbenecidThe serum concentration of Sparfloxacin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Sparfloxacin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Sparfloxacin can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Sparfloxacin.Approved
PropafenoneThe serum concentration of Sparfloxacin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Sparfloxacin can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Sparfloxacin can be increased when it is combined with Protriptyline.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
QuercetinThe serum concentration of Sparfloxacin can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Sparfloxacin can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Sparfloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Sparfloxacin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Sparfloxacin can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Sparfloxacin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Sparfloxacin can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Sparfloxacin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Sparfloxacin can be increased when it is combined with Regorafenib.Approved
RepaglinideSparfloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Sparfloxacin can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the neuroexcitatory activities of Sparfloxacin.Experimental, Investigational
RifampicinThe serum concentration of Sparfloxacin can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Sparfloxacin can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Sparfloxacin.Approved
RitonavirThe serum concentration of Sparfloxacin can be decreased when it is combined with Ritonavir.Approved, Investigational
RofecoxibRofecoxib may increase the neuroexcitatory activities of Sparfloxacin.Investigational, Withdrawn
RolapitantThe serum concentration of Sparfloxacin can be increased when it is combined with Rolapitant.Approved
RosiglitazoneSparfloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Sparfloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Sparfloxacin.Approved
SaquinavirThe serum concentration of Sparfloxacin can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinSparfloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe serum concentration of Sparfloxacin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Sparfloxacin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SertralineThe serum concentration of Sparfloxacin can be increased when it is combined with Sertraline.Approved
SevelamerSevelamer can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SimeprevirThe serum concentration of Sparfloxacin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Sparfloxacin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Sparfloxacin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinSparfloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SorafenibThe serum concentration of Sparfloxacin can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Sparfloxacin can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
St. John's WortThe serum concentration of Sparfloxacin can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Sparfloxacin can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Sparfloxacin can be decreased when it is combined with Streptozocin.Approved
Strontium ranelateThe serum concentration of Sparfloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Sparfloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineSparfloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSparfloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SulfinpyrazoneThe serum concentration of Sparfloxacin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSparfloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Sparfloxacin.Approved
SumatriptanThe serum concentration of Sparfloxacin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sparfloxacin can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Withdrawn
TacrineThe serum concentration of Sparfloxacin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Sparfloxacin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Sparfloxacin can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Sparfloxacin can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Sparfloxacin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Sparfloxacin can be increased when it is combined with Temsirolimus.Approved
TenoxicamTenoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Sparfloxacin.Vet Approved
TerazosinThe serum concentration of Sparfloxacin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Sparfloxacin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Sparfloxacin.Approved
TesmilifeneThe serum concentration of Sparfloxacin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Sparfloxacin can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sparfloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
TicagrelorThe serum concentration of Sparfloxacin can be increased when it is combined with Ticagrelor.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Sparfloxacin.Approved
TolazamideSparfloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideSparfloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Sparfloxacin.Approved
TolvaptanThe serum concentration of Sparfloxacin can be increased when it is combined with Tolvaptan.Approved
TranilastTranilast may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sparfloxacin.Approved, Investigational
TrazodoneThe serum concentration of Sparfloxacin can be decreased when it is combined with Trazodone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Sparfloxacin.Approved, Vet Approved
TrifluoperazineThe serum concentration of Sparfloxacin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Sparfloxacin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Sparfloxacin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Sparfloxacin can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Sparfloxacin.Approved
TroleandomycinThe serum concentration of Sparfloxacin can be increased when it is combined with Troleandomycin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Sparfloxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Sparfloxacin.Approved, Investigational
VenlafaxineThe serum concentration of Sparfloxacin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Sparfloxacin can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Sparfloxacin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Sparfloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Sparfloxacin can be increased when it is combined with Vinorelbine.Approved, Investigational
WarfarinSparfloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Sparfloxacin can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Guillaume Conrath, “Solution of sparfloxacin, its preparation and salt of which it is composed.” U.S. Patent US5478829, issued May, 1987.

US5478829
General ReferencesNot Available
External Links
ATC CodesJ01MA09
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (13.3 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9845
Blood Brain Barrier-0.967
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.8118
P-glycoprotein inhibitor INon-inhibitor0.9345
P-glycoprotein inhibitor IINon-inhibitor0.9183
Renal organic cation transporterNon-inhibitor0.8154
CYP450 2C9 substrateNon-substrate0.8794
CYP450 2D6 substrateNon-substrate0.8787
CYP450 3A4 substrateNon-substrate0.6465
CYP450 1A2 substrateNon-inhibitor0.82
CYP450 2C9 inhibitorNon-inhibitor0.84
CYP450 2D6 inhibitorNon-inhibitor0.89
CYP450 2C19 inhibitorNon-inhibitor0.8339
CYP450 3A4 inhibitorNon-inhibitor0.85
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7377
Ames testAMES toxic0.6341
CarcinogenicityNon-carcinogens0.8044
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9265 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.967
hERG inhibition (predictor II)Non-inhibitor0.7961
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4795751 No1993-02-042010-02-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.113 mg/mLALOGPS
logP-0.07ALOGPS
logP-0.043ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5.75ChemAxon
pKa (Strongest Basic)8.79ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area98.9 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity101.69 m3·mol-1ChemAxon
Polarizability38.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxylic acids
Direct ParentQuinoline carboxylic acids
Alternative Parents
Substituents
  • Quinoline-3-carboxylic acid
  • N-arylpiperazine
  • Fluoroquinolone
  • Dihydroquinolone
  • Aminoquinoline
  • Dihydroquinoline
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • Fluorobenzene
  • Benzenoid
  • Pyridine
  • Primary aromatic amine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779 ]
  4. Taba H, Kusano N: Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob Agents Chemother. 1998 Sep;42(9):2193-6. [PubMed:9736534 ]
  5. Fukuda H, Hori S, Hiramatsu K: Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Aug;42(8):1917-22. [PubMed:9687384 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Galbraith KM, Ng AC, Eggers BJ, Kuchel CR, Eggers CH, Samuels DS: parC mutations in fluoroquinolone-resistant Borrelia burgdorferi. Antimicrob Agents Chemother. 2005 Oct;49(10):4354-7. [PubMed:16189120 ]
  4. Oyamada Y, Ito H, Fujimoto K, Asada R, Niga T, Okamoto R, Inoue M, Yamagishi J: Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol. 2006 Jun;55(Pt 6):729-36. [PubMed:16687591 ]
  5. Pan XS, Yague G, Fisher LM: Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrob Agents Chemother. 2001 Nov;45(11):3140-7. [PubMed:11600369 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Sasabe H, Tsuji A, Sugiyama Y: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther. 1998 Mar;284(3):1033-9. [PubMed:9495864 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A: Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol. 2001 May;53(5):699-709. [PubMed:11370709 ]
  2. Cormet-Boyaka E, Huneau JF, Mordrelle A, Boyaka PN, Carbon C, Rubinstein E, Tome D: Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Antimicrob Agents Chemother. 1998 Oct;42(10):2607-11. [PubMed:9756763 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23